Overall, the findings suggest that elevations in circulating GFAP may occur early in the neurodegenerative disease process, highlighting the potential utility of the biomarker for aiding dementia risk prediction and improving stratification in clinical trials targeting the preclinical disease stage. This evidence concerns the gene GFAP and dementia.